Deep inside every cell, lysosomes act as the cell's recycling plant — breaking down old proteins, clearing misfolded aggregates, and recycling the parts. Maintaining the right internal pH (around 4.5–5.0) is essential for the digestive enzymes inside to work. TMEM175 encodes a lysosomal ion channel¹¹ lysosomal ion channel
proton-activated, proton-selective K+/H+ channel that fine-tunes lysosomal acidity — a molecular pressure-relief valve. The rs34311866 C allele introduces a methionine-to-threonine substitution at position 393 that partially disables this valve, with consequences that reach all the way to Parkinson's disease risk.

The Mechanism

The M393T substitution reduces channel current amplitude²² The M393T substitution reduces channel current amplitude compared to wild-type, placing function midway between the functional and knockout states. When the channel cannot adequately regulate lysosomal pH, two downstream failures occur: First, autophagosome clearance is impaired³³ autophagosome clearance is impaired — cellular debris builds up rather than being digested. Second, and most critically for neurodegeneration, alpha-synuclein — the protein that aggregates into Lewy bodies in Parkinson's disease — accumulates in its phosphorylated (aggregation-prone) form. Wild-type TMEM175 overexpression reduces phospho-α-synuclein; M393T overexpression does not. The channel is also considered a druggable target for lysosomal dysfunction in neurodegeneration⁴⁴ druggable target for lysosomal dysfunction in neurodegeneration, with selective inhibitors and activators under active investigation.

The Evidence

The genetic signal is one of the strongest in Parkinson's disease research. Chang et al. 2017 (Nature Genetics) identified the TMEM175 locus with OR 1.23, p=1×10⁻⁵⁰⁵⁵ Chang et al. 2017 (Nature Genetics) identified the TMEM175 locus with OR 1.23, p=1×10⁻⁵⁰ across 26,035 cases and 403,190 controls — one of 17 novel PD risk loci. The Nalls et al. 2019 Lancet Neurology meta-analysis of 37,688 cases and 1.4 million controls⁶⁶ Nalls et al. 2019 Lancet Neurology meta-analysis of 37,688 cases and 1.4 million controls confirmed the locus among 90 independent genome-wide significant signals. Functional studies by Wie et al. (Nature, 2021) quantified the C allele OR at 1.26 [95% CI 1.22–1.31]⁷⁷ Wie et al. (Nature, 2021) quantified the C allele OR at 1.26 [95% CI 1.22–1.31] and found that C carriers in the University of Pennsylvania and PPMI cohorts showed faster motor decline (p=0.032) and faster cognitive decline (p=0.005) after diagnosis. Beyond PD, the Blauwendraat et al. 2019 age-at-onset GWAS⁸⁸ Blauwendraat et al. 2019 age-at-onset GWAS (28,568 cases) found rs34311866 p.M393T is the primary coding signal for earlier PD onset. The Krohn et al. 2022 RBD GWAS (Nature Communications)⁹⁹ Krohn et al. 2022 RBD GWAS (Nature Communications) then identified TMEM175 as one of five loci for REM sleep behavior disorder — a prodromal synucleinopathy — shared across RBD, PD, and dementia with Lewy bodies.

Practical Actions

Carriers of the C allele cannot fix the M393T variant, but they can support the cellular processes that compensate for reduced lysosomal function. The principal strategy is maintaining autophagic flux — the rate at which cells clear protein waste — through targeted supplementation and lifestyle choices. Trehalose, a disaccharide that activates the TFEB transcription factor independently of mTOR, has documented preclinical effects on TMEM175-dependent clearance pathways. Spermidine similarly induces autophagy via eIF5A hypusination. Urolithin A (a gut metabolite of ellagic acid) activates mitophagy and has Phase II trial data in humans. These are not generic supplements — they specifically address the autophagy-lysosomal axis impaired by M393T. Neurological monitoring for early-onset cognitive or motor changes is warranted, particularly given evidence of accelerated decline after diagnosis.

Interactions

TMEM175 sits in the same autophagy-lysosomal pathway¹⁰¹⁰ autophagy-lysosomal pathway as GBA1 (glucocerebrosidase) — the strongest known genetic risk factor for PD (rs76763715, N370S). Both genes affect lysosomal function and alpha-synuclein clearance, but through distinct mechanisms: TMEM175 at the pH-regulation step, GBA1 at the enzymatic glucosphingolipid-hydrolysis step. Carriers of risk alleles in both genes may face compounded impairment of lysosomal alpha-synuclein clearance. rs2736990 (SNCA intron 4) increases alpha-synuclein expression levels — a separate upstream contributor to the same aggregation cascade. The combination of elevated substrate (SNCA) and impaired clearance (TMEM175) represents a convergent risk architecture worth capturing as a compound interaction candidate.

The GLP-1 receptor¹¹ GLP-1 receptor
Glucagon-like peptide-1 receptor, the molecular target of Ozempic, Wegovy, and Saxenda is the direct drug target for some of the most prescribed medications in modern medicine: semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and exenatide (Byetta). Unlike most pharmacogenomic variants that affect drug metabolism enzymes, rs3765467 changes the drug target itself — replacing arginine with glutamine at position 131 in the receptor's extracellular binding domain. This variant is strikingly population-specific: carried by about 21% of East Asians but fewer than 0.3% of Europeans.

The Mechanism

Position 131 sits in exon 4 of GLP1R²² exon 4 of GLP1R
The extracellular N-terminal domain where GLP-1 and its drug analogues make initial contact with the receptor, within the ligand-binding pocket that makes direct contact with GLP-1 and its pharmaceutical mimics. Arginine at this position carries a positive charge that participates in electrostatic interactions stabilizing ligand binding. The glutamine substitution removes this charge, altering receptor conformation and downstream cAMP signaling³³ cAMP signaling
Cyclic adenosine monophosphate, the key second messenger that triggers insulin release from pancreatic beta cells. In beta-cell models, the variant receptor shows significantly reduced glucose-stimulated insulin secretion and increased apoptosis⁴⁴ significantly reduced glucose-stimulated insulin secretion and increased apoptosis
Li et al. GLP1R SNPs rs3765467 and rs10305492 affect beta-cell insulin secretory capacity. DNA Cell Biol, 2020. However, in living human carriers, the picture is paradoxically reversed — healthy heterozygotes show over 100% greater beta-cell responsivity to GLP-1⁵⁵ healthy heterozygotes show over 100% greater beta-cell responsivity to GLP-1
Sathananthan et al. Common genetic variation in GLP1R and insulin secretion. Diabetes Care, 2010, suggesting compensatory mechanisms that amplify the signal in vivo.

The Evidence

The strongest genetic evidence comes from a large East Asian exome-wide study⁶⁶ large East Asian exome-wide study
Kwak et al. Nonsynonymous variants in PAX4 and GLP1R are associated with type 2 diabetes. Diabetes, 2018 of over 17,000 individuals, which showed the A allele is protective against type 2 diabetes at genome-wide significance (OR 0.84, P = 3.55 x 10^-8). This is consistent with the enhanced insulin secretion seen in carriers.

For drug response, two key findings stand out. A Korean pharmacogenomic study⁷⁷ Korean pharmacogenomic study
Han et al. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors. Medicine, 2016 of 246 T2D patients found A allele carriers had twice the odds of responding to DPP-4 inhibitors (OR 2.00, 95% CI 1.03-3.89), with greater HbA1c reduction (1.3% vs 0.9%, P = 0.022). In contrast, a Chinese prospective cohort⁸⁸ Chinese prospective cohort
Guan et al. Association between GLP1R gene polymorphism and treatment response to GLP1R agonists. Eur J Clin Pharmacol, 2022 of 156 patients found the wild-type GG genotype had significantly better HbA1c reduction on GLP-1 agonists (1.7% vs 0.8%, P = 0.002) and higher rates of reaching target HbA1c (50.9% vs 23.8%).

This apparent contradiction likely reflects different drug mechanisms: DPP-4 inhibitors raise endogenous GLP-1 to physiological levels (where the variant receptor's enhanced sensitivity is advantageous), while GLP-1 agonists deliver pharmacological doses that may overwhelm the altered receptor. Supporting this, A allele carriers also show increased gastrointestinal side effects on liraglutide⁹⁹ increased gastrointestinal side effects on liraglutide
Long et al. Eur J Clin Pharmacol, 2022 (P = 0.007), with a dose-dependent relationship between A allele count and nausea severity.

Practical Implications

The core clinical question for carriers is which GLP-1-based therapy will work best. The evidence suggests that if the primary goal is glycemic control, DPP-4 inhibitors (sitagliptin, saxagliptin) may be more effective than expected for A allele carriers. If a GLP-1 agonist (semaglutide, liraglutide) is chosen — particularly for weight loss — slower dose titration and close monitoring of both gastrointestinal tolerance and glycemic response are warranted.

Interactions

The parallel GLP1R variant rs6923761 (Gly168Ser) also modifies GLP-1 agonist response but through a distinct mechanism — primarily affecting gastric emptying rate and weight loss magnitude. Carriers of both Arg131Gln and Gly168Ser may have compounded alterations in GLP-1 agonist response affecting both glycemic control and weight loss. The related GIPR variant rs10423928 affects the parallel incretin pathway and may further modify response to dual GIP/GLP-1 agonists like tirzepatide (Mounjaro). The intracellular GLP1R variant rs10305492 (Ala316Thr) also reduces beta-cell signaling and may compound with Arg131Gln to create a more severely impaired receptor profile.

The MTRR gene encodes methionine synthase reductase, a flavoprotein that keeps the methylation cycle running by reactivating methionine synthase (MTR) after oxidative inactivation. Without functional MTRR, MTR can't recycle homocysteine to methionine, and the entire one-carbon methylation machinery stalls. The well-studied MTRR A66G variant (rs1801394) directly alters the protein, but MTRR also carries intronic variants that appear to influence gene regulation in subtler ways. rs3776467 is one such variant — an intronic substitution at position c.401+827 that has no direct effect on the MTRR protein sequence, yet shows a reproducible association with DNA methylation outcomes in specific contexts.

The Mechanism

Because rs3776467 sits within an intron ¹¹ Intronic variants can influence gene expression through effects on splicing, branch point usage, and regulatory element binding without changing the amino acid sequence of the protein, it does not alter the MTRR protein. Its effects are likely regulatory — modulating the level or splicing of MTRR transcripts rather than the enzyme's catalytic activity. The functional consequence of reduced MTRR expression would parallel the missense A66G effect: less efficient B12 reactivation, impaired MTR activity, and downstream effects on homocysteine remethylation and global DNA methylation. The precise regulatory mechanism has not been characterized.

The Evidence

The primary evidence comes from the Lovelace Smokers Cohort²² Lovelace Smokers Cohort
Flores KG et al. Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers. Carcinogenesis, 2012, a study of 907 non-Hispanic white smokers examining promoter hypermethylation in lung epithelium. In this cohort, the G allele of rs3776467 was associated with reduced risk for high promoter hypermethylation: OR 0.57 (95% CI: 0.42–0.77, p=0.0003) overall, driven almost entirely by females (females: OR 0.64, 95% CI: 0.49–0.85, p=0.002; males: OR 0.92, 95% CI: 0.57–1.47, p=0.72). The AA genotype — homozygous for the reference allele — was associated with higher methylation risk, while carrying at least one G allele was protective in women.

A colorectal cancer cohort study³³ colorectal cancer cohort study
Wang Y et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients, 2022 of 532 CRC patients (Newfoundland, median follow-up 6.4 years) identified significant interactions between rs3776467 and pre-diagnostic alcohol consumption: protective alleles of rs3776467 were associated with superior overall survival, but only in patients consuming below-median alcohol. This interaction suggests the variant's effect on one-carbon metabolism is amplified by lifestyle factors that disrupt folate and methyl-donor homeostasis.

The evidence is currently emerging — two studies, both in specific populations (smokers, CRC patients), with no direct functional validation of the intronic variant's molecular effect and no homocysteine association data. The sex-specific nature of the primary finding limits applicability.

Practical Actions

For carriers of the AA genotype (homozygous reference, most common in Europeans), the primary actionable insight is context-dependent: the elevated methylation risk appears most relevant in the setting of smoking or high alcohol intake that disrupts the one-carbon cycle. Optimizing methylation nutrition — particularly active B12 forms and methylfolate — supports MTRR function regardless of this variant. For women who smoke, this SNP adds to the case for prioritizing methylation support.

Alcohol consumption deserves specific mention: the interaction with rs3776467 and colorectal cancer survival suggests that alcohol's known methylation- disrupting effects may be modulated by this variant. Reducing alcohol intake supports both folate-dependent methylation and the protective effect of the G allele.

Interactions

rs3776467 operates in the same MTRR pathway as the coding variant rs1801394 (A66G). Combined impairment — AA at rs3776467 plus GG at rs1801394 — could theoretically reduce MTRR function through both regulatory and catalytic mechanisms. The upstream MTHFR variants (rs1801133) affect methylfolate supply, and MTR variants (rs1805087) affect the reaction MTRR supports; weakness at multiple points compounds the burden on the methylation cycle. No published study has assessed the combined genotype of rs3776467 with rs1801394.

Deep inside the hypothalamus, a cluster of roughly 20,000 neurons called the suprachiasmatic nucleus (SCN)¹¹ suprachiasmatic nucleus (SCN)
The brain's master circadian clock, located in the hypothalamus above the optic chiasm; it generates and coordinates ~24-hour biological rhythms throughout the body fires in near-perfect 24-hour cycles, orchestrating sleep, hormone release, and metabolism across every cell in the body. Keeping those neurons synchronized with each other — not just cycling individually — requires a molecular conductor. RGS16²² RGS16
Regulator of G-protein Signaling 16; a protein that accelerates the inactivation of G-protein alpha subunits, terminating cAMP signaling pulses is that conductor.

The rs516134 variant sits approximately 20 kilobases downstream of the RGS16 gene, in a regulatory region that influences how much RGS16 the SCN produces. Carriers of the C allele — the minor allele at this position — tend to wake earlier, feel alert sooner after rising, and perform best in the morning. This makes rs516134 the top replicated chronotype hit in human genetics, having emerged independently in three major genome-wide association studies spanning nearly 700,000 people.

The Mechanism

RGS16 exerts its circadian influence by gating cAMP³³ cAMP
Cyclic AMP (cyclic adenosine monophosphate), a second messenger that amplifies signals from G-protein-coupled receptors; in the SCN, timed cAMP pulses coordinate neuron-to-neuron communication production in the SCN. In the intact clock, RGS16 protein levels rise and fall over the 24-hour cycle, creating a time window each day during which cAMP can accumulate. This rhythmic cAMP pulse synchronizes the dorsomedial SCN neurons (which drive the rest of the body) with the ventrolateral neurons (which receive light input from the retina).

Doi et al. (2011)⁴⁴ Doi et al. (2011)
Doi M et al. Circadian regulation of intracellular G-protein signalling mediates intercellular synchrony and rhythmicity in the suprachiasmatic nucleus. Nature Communications, 2011 showed that when RGS16 is deleted in mice, the circadian cAMP rhythm collapses entirely — and the behavioral circadian period lengthens. A longer internal period means the clock runs slow relative to the 24-hour day, causing the animal (and, by analogy, the human) to drift toward later and later timing — exactly the phenotype associated with low RGS16 activity.

The rs516134 C allele appears to support higher regulatory-region activity, boosting RGS16 expression, tightening cAMP gating in the SCN, and shortening the effective period toward a morning-shifted chronotype. The molecular details of how the variant changes transcription factor binding at this regulatory element remain under active investigation.

The Evidence

The RGS16 locus has the distinction of being the most strongly replicated single locus in human chronotype genetics. Three independent large-scale GWAS, each using different populations and methods, have all converged on this region.

Jones et al. (2016)⁵⁵ Jones et al. (2016)
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 analyzed 128,266 UK Biobank participants and identified rs516134 as the lead SNP at the RGS16 locus, with the C allele conferring an odds ratio of 1.21 (95% CI 1.15–1.27) for morningness at P=3×10⁻¹².

Hu et al. (2016)⁶⁶ Hu et al. (2016)
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nature Communications, 2016 independently studied 89,283 23andMe participants and found the same locus — represented by the linked variant rs12736689 — as the single most significant chronotype hit at P=7×10⁻¹⁸. Seven of the 15 significant loci fell near known circadian genes, with RGS16 the strongest.

The definitive meta-analytic confirmation came from Jones et al. (2019)⁷⁷ Jones et al. (2019)
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019, which expanded the catalog of chronotype loci from 24 to 351 in 697,828 individuals. The pathway analysis implicated cAMP signaling, circadian regulation, and retinal/hypothalamic expression — all converging on the biology explained by RGS16. Using Mendelian randomization, the study showed that being a morning person is causally associated with better mental health outcomes.

Practical Implications

For carriers of TT (the common genotype), circadian timing is close to the population average — not sharply morning or evening, but with a gentle evening lean compared to C allele carriers. The practical implication is awareness: your biological clock has no strong push toward morningness, so environmental factors (light exposure, meal timing, sleep scheduling) matter more in shaping your daily rhythm.

For carriers of one or two C alleles, the clock runs slightly faster, making it easier to wake early and fall asleep earlier. This is an advantage in most modern work schedules but can become a liability when evening social or professional demands conflict with an early-dimming internal clock. Evening light exposure and slightly later meal timing can extend alertness into the evening when needed.

Light therapy is the most evidence-based intervention for chronotype adjustment in either direction. Morning bright light (10,000 lux) reinforces early timing; evening blue-light reduction prevents unwanted advance for C allele carriers who want to stay up later.

Interactions

rs516134 acts within the same circadian feedback network as variants in CLOCK (rs1801260), PER3 (rs5751876), and the VIP receptor gene. These SNPs operate at different nodes of the circadian oscillator: CLOCK affects transcription factor stability, PER3 affects the negative feedback arm, and RGS16 affects intercellular synchrony via cAMP. Carriers of evening-tendency alleles at multiple loci may experience additive chronotype shifts beyond what any single SNP predicts.

The GPR176–Gz–RGS16 axis is also under investigation for its relationship to human chronotype variation more broadly (PMID 28502923), and several nominally associated variants upstream of RGS16 have been identified in the larger GWAS datasets that may refine the functional signal at this locus.

Endothelial lipase (EL) is an enzyme secreted by vascular endothelial cells that hydrolyzes the phospholipid coat of HDL particles¹¹ HDL particles
high-density lipoprotein — the "good cholesterol" responsible for reverse cholesterol transport from arteries to the liver. Higher endothelial lipase activity degrades HDL faster, lowering both HDL particle count and size. The LIPG gene encodes this enzyme, and rs6507931 is an intronic variant that modulates its expression — with the T allele associated with altered HDL dynamics, particularly under sedentary conditions.

The Mechanism

rs6507931 sits in intron 24 of LIPG (c.1155-108, transcript variant 2) on chromosome 18q21.1. As an intronic variant it does not change the amino acid sequence of the EL protein, but it likely affects splicing efficiency or transcriptional regulation of LIPG expression. Higher LIPG expression means more phospholipid hydrolysis of HDL particles, producing smaller, cholesterol-depleted HDL remnants and reducing overall HDL-C. The T allele tags a haplotype associated with this pattern of increased EL activity, especially when physical activity levels are low — aerobic exercise is known to suppress LIPG expression in striated muscle tissue, protecting HDL from excessive degradation.

The Evidence

The primary evidence for rs6507931 comes from the GOLDN study²² GOLDN study
Smith CE et al. Physical inactivity interacts with an endothelial lipase polymorphism to modulate high density lipoprotein cholesterol in the GOLDN study. Atherosclerosis, 2009, a community-based family study of 1,123 White adults. Participants with the TT genotype who logged high daily screen time (≥2.6 hours) showed lower total HDL-C, reduced large HDL particle concentrations, smaller HDL particle sizes, and elevated small LDL concentrations compared to CT and CC carriers at the same activity level. The effect reached statistical significance (P<0.05) across multiple HDL measures and was more pronounced in women than men.

Halverstadt et al.³³ Halverstadt et al.
Halverstadt A et al. High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Metabolism, 2003 studied 83 sedentary adults aged 50–75 who underwent aerobic exercise training. At baseline, CT/TT carriers showed lower HDL(2NMR)-C (12±1.0 vs 17±1.1 mg/dL, P=.002) and lower integrated HDL subfractions. After training, CC homozygotes gained 4.4 mg/dL HDL-C versus only 1.9 mg/dL in CT/TT carriers (P=.04), indicating that the T allele also blunts the HDL response to aerobic exercise.

Vergeer et al.⁴⁴ Vergeer et al.
Vergeer M et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis, 2010 examined rs6507931 in relation to coronary artery disease and deep vein thrombosis. While an initial DVT association (OR 2.04) appeared in one cohort, it could not be replicated, confirming this variant is best classified as a modifier of HDL metabolism rather than a direct cardiovascular risk allele under all conditions.

Practical Actions

The clearest actionable implication of the T allele is that regular aerobic activity is especially important for maintaining HDL-C and HDL particle quality. Exercise suppresses LIPG expression in skeletal and cardiac muscle — T allele carriers who remain sedentary lose this protective downregulation and experience greater HDL degradation. Specifically, high-intensity aerobic activity (cycling, running, swimming) at ≥150 minutes per week has been shown to elevate HDL-C and HDL particle size in LIPG-variant carriers. Omega-3 fatty acids (EPA/DHA) support HDL particle remodeling through a complementary mechanism independent of LIPG activity.

Monitoring the fasting lipid panel — specifically HDL-C and ideally HDL particle size via NMR lipoprotein analysis — provides the most informative tracking for TT individuals, because total HDL-C alone may underestimate the shift toward smaller, less cardioprotective HDL particles.

Interactions

The coding variant rs2000813 (Thr111Ile, T111I) in LIPG exon 3 is the most studied functional variant in this gene and affects EL enzyme activity directly. Carriers of the rs2000813 minor allele (Ile111) show modest HDL-C elevation. rs6507931 and rs2000813 are in linkage disequilibrium in some populations and were studied together in the Hutter et al. haplotype analysis of Japanese Americans (PMID 16023652). The combined haplotype effect on HDL subfractions and apolipoprotein AI levels exceeded either variant alone.

The PPARG gene encodes PPARγ¹¹ PPARγ
Peroxisome Proliferator-Activated Receptor Gamma — a nuclear receptor that controls adipocyte differentiation, fat storage, insulin sensitisation, and lipid metabolism throughout the body, the master regulator of fat-cell biology. The gene has multiple isoforms generated from distinct promoters. The C-689T variant (rs7649970) sits in the P2 promoter — the one that exclusively drives expression of the PPARγ2 isoform²² PPARγ2 isoform
PPARγ2 is distinguished from PPARγ1 by a 28-amino-acid N-terminal extension and is expressed almost exclusively in adipose tissue, where it is the dominant regulator of adipogenesis and insulin sensitisation, which is predominant in adipose tissue and is the isoform studied in the landmark Pro12Ala literature. Unlike Pro12Ala (rs1801282), which changes the receptor protein itself, C-689T changes how much of the protein gets made in the first place.

The Mechanism

The C-689T polymorphism is a C-to-T transition at position -689 in the PPARγ2 P2 promoter, within a region that contains a putative GATA transcription factor³³ GATA transcription factor
GATA factors (GATA2, GATA3) are zinc-finger transcription factors that bind GATA DNA sequences and regulate gene expression in adipose, hematopoietic, and endothelial cells binding site. Meirhaeghe et al. (2005)⁴⁴ Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 demonstrated that GATA2 and GATA3 proteins bind the wild-type C-689 site but fail to bind the mutated T-689 site. The key consequence: the T allele renders the P2 promoter less active at baseline, resulting in reduced PPARγ2 expression in adipose tissue. Reduced PPARγ2 impairs adipocyte differentiation and insulin sensitisation capacity, shifting the metabolic balance toward higher circulating LDL-cholesterol, elevated triglycerides, and atherogenic lipid profiles.

The Evidence

The discovery study by Meirhaeghe et al. (2005)⁵⁵ Meirhaeghe et al. (2005)
Meirhaeghe A et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005 examined 1,155 French subjects and found that T allele carriers had significantly elevated body weight and LDL-cholesterol concentrations compared with CC homozygotes. A haplotype analysis showed that when C-689T interacts with the C1431T and Pro12Ala variants in a specific haplotype combination, the association with higher LDL and body weight is amplified.

Two Chinese Han studies quantified the cardiovascular risk directly. Li et al. (2008)⁶⁶ Li et al. (2008)
Li JP et al. Study on the association of -689C/T polymorphism in the PPARgamma2 promoter with myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2008 enrolled 194 myocardial infarction patients and 693 controls and found the T allele was an independent risk factor for MI (OR 2.13, 95% CI 1.21–3.74, P = 0.009) after adjusting for traditional risk factors. T allele carriers also showed significantly elevated total cholesterol. Li et al. (2017)⁷⁷ Li et al. (2017)
Li JP et al. Functional variant of C-689T in the peroxisome proliferator-activated receptor-γ2 promoter is associated with coronary heart disease in Chinese nondiabetic Han people. Chin Med Sci J, 2017 extended this to 455 CHD patients and 693 controls without CHD, finding the T allele independently associated with CHD (OR 1.67, 95% CI 1.03–2.71, P = 0.037) and confirmed elevated total cholesterol in T carriers.

A European replication came from Dallongeville et al. (2009)⁸⁸ Dallongeville et al. (2009)
Dallongeville J et al. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res, 2009 using the PRIME study cohort (249 CHD cases, 494 controls; middle-aged men from France and Northern Ireland). TT homozygotes showed OR 3.43 (95% CI 0.96–12.27, P = 0.058) — statistically marginal owing to the rarity of TT, but biologically consistent with the Chinese data. In a haplotype study of 1,155 French subjects, Meirhaeghe et al. (2005, Diabetes)⁹⁹ Meirhaeghe et al. (2005, Diabetes)
Meirhaeghe A et al. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes, 2005 found that a haplotype carrying the T allele was enriched in metabolic syndrome cases (OR up to 2.47).

Practical Implications

The T allele is carried by roughly 13% of Europeans and 17% of Africans, making CT heterozygotes (~23% of Europeans) a sizeable group for whom LDL monitoring and lipid management are specifically warranted. The TT homozygote (roughly 2% of the population globally) carries the highest expression deficit but is too rare for well-powered homozygote-specific trials. The primary actionable markers are LDL-cholesterol and total cholesterol — both consistently elevated in T allele carriers across populations.

Interactions

rs7649970 is one of four common PPARG variants that co-segregate in haplotype blocks. The most clinically relevant interactions are with rs1801282 (Pro12Ala) and rs3856806 (C1431T). The G-T-Ala haplotype (rs10865710 G / rs7649970 T / rs1801282 Ala) was associated with the highest LDL and body weight burden in the Meirhaeghe 2005 cohort. Additionally, rs7649970 and rs10865710 act through independent mechanisms — rs10865710 disrupts a CREB2 enhancer element while rs7649970 disrupts GATA binding in the PPARγ2 P2 promoter — meaning carriers of risk alleles at both loci face compounded suppression of PPARγ expression via separate molecular paths.

The CHI3L1 gene encodes YKL-40, a chitinase-like glycoprotein that functions as a biomarker and mediator of tissue inflammation. Elevated YKL-40 is a consistent feature of active asthma, allergic airway disease, and cardiovascular inflammation; levels track with disease severity across all three domains. The CHI3L1 locus on chromosome 1q32.1 contains a cluster of genetic variants — each contributing independently to how much YKL-40 your body produces. rs2297839 is an intronic variant at this locus that co-associates with lower YKL-40 levels, adding a third independent regulatory signal alongside the well-characterized promoter (rs4950928) and upstream eQTL (rs10399931) variants.

The Mechanism

rs2297839 sits within the body of the CHI3L1 gene at chr1:203183056 (GRCh38), approximately 3.7 kb from the main promoter variant rs4950928. The variant is annotated as intronic on the minus-strand gene. The precise molecular mechanism by which rs2297839 influences CHI3L1 expression has not been published in isolation — it was identified as a tag SNP among 15 CHI3L1 variants in a population study rather than through a dedicated functional assay. However, its co-classification with four other CHI3L1 variants (rs10399931, rs1538372, rs2071580, rs4950928) as YKL-40-lowering alleles in Xu et al. 2021¹¹ Xu et al. 2021
Xu T et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence. J Cell Mol Med, 2021 indicates it is part of the same regulatory architecture. The T allele at rs2297839 is consistently associated with lower circulating YKL-40, mirroring the effect of protective alleles at rs4950928 and rs10399931.

Intronic variants can modulate gene expression through several mechanisms: altering splicing enhancer or silencer sequences²² splicing enhancer or silencer sequences
Intronic regulatory elements that recruit splicing factors, affecting which exons are included in the final mRNA, disrupting chromatin loop anchor points, or tagging functional variants in linkage disequilibrium. Given that the Guerra et al. birth cohort study found that CHI3L1 alleles linked to lower YKL-40 are associated with higher DNA methylation at five CpG sites, epigenetic mediation is a plausible route for rs2297839 as well.

The Evidence

The primary evidence for rs2297839 comes from a nested case-control study by Xu et al.³³ nested case-control study by Xu et al.
Xu T et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: A population-based nested case-control study in China. J Cell Mol Med, 2021 of 507 matched case-control pairs within a Chinese prospective cohort. Among 15 CHI3L1 tag SNPs, rs2297839 was one of five variants associated with lower YKL-40 levels. In the male sub-analysis, heterozygous and rare homozygous T-allele carriers had a significantly lower risk of hypertension compared with major homozygote (CC) carriers (OR 0.49, 95% CI 0.26–0.91).

The biological plausibility rests on the well-established role of YKL-40 in vascular inflammation. Lee et al. 2010⁴⁴ Lee et al. 2010
Lee C-G et al. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. J Allergy Clin Immunol, 2010 demonstrated that YKL-40 activates macrophages, promotes Th2 polarization, and drives tissue remodeling — mechanisms relevant to both airway disease and atherosclerosis. Lower genetically-determined YKL-40 should therefore dampen inflammatory signaling across multiple tissue compartments.

It is important to note that rs2297839 has only one direct study, and the hypertension association was limited to male subjects in a Chinese cohort. Independent replication in diverse populations and dedicated functional characterization are needed before the evidence level can be upgraded beyond emerging.

Practical Actions

For CC homozygotes, the genotype represents the common YKL-40-higher baseline, shared by approximately 64% of people globally. Serum YKL-40 is the most direct readout of combined CHI3L1 genetic status — useful for tracking inflammatory activity in asthma, COPD, or cardiovascular workups.

For CT and TT carriers, the T allele is associated with a lower inflammatory setpoint at this locus. In a clinical YKL-40 result, T-allele carriers at rs2297839 — especially when combined with protective alleles at the promoter (rs4950928 GG) or eQTL (rs10399931 TT) — are likely to show lower-than-average values that reflect their genetics rather than a pathological deficiency.

Interactions

rs2297839 operates within the same CHI3L1 regulatory cluster as rs4950928 (promoter, the strongest YKL-40 determinant), rs10399931 (upstream regulatory, acts via a post-transcriptional mechanism), and rs872129 (a third independent eQTL signal confirmed by conditional analysis in Chou et al. 2024). The intronic variant rs12141494 adds a fourth independent signal that specifically affects airway tissue YKL-40 and lung function severity in asthma. Each variant in this cluster represents a partial contribution to the genetic YKL-40 set-point — carriers of protective alleles at multiple CHI3L1 variants benefit from additive suppression of this inflammatory axis.

The rs356182 variant sits approximately 19 kilobases downstream of the SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) is the first gene linked to Parkinson's disease and encodes a protein that forms the pathological hallmark of PD — Lewy bodies, in a brain-specific regulatory region marked by H3K27Ac histone modifications. This variant is one of the most statistically significant genetic associations with Parkinson's disease²² This variant is one of the most statistically significant genetic associations with Parkinson's disease
With a meta-analysis p-value of 1.85 × 10⁻⁸², rs356182 ranks among the strongest non-coding PD risk variants, consistently identified across multiple large-scale genome-wide association studies³³ multiple large-scale genome-wide association studies. The G allele increases PD risk with an odds ratio of 1.34 to 1.47⁴⁴ odds ratio of 1.34 to 1.47 depending on the population studied, and is robustly represented at approximately 37% frequency globally.

What makes rs356182 particularly interesting is that it doesn't follow a simple story. The risk allele (G) increases your chances of developing Parkinson's, but if you do develop the disease with GG genotype, you're more likely to have a tremor-predominant form with slower motor progression⁵⁵ tremor-predominant form with slower motor progression compared to the more aggressive postural instability and gait disorder (PIGD) phenotype. This paradox — higher disease risk but milder disease course — reveals the complexity of how this variant influences neurodegenerative processes.

The Mechanism

rs356182 resides within a genetic enhancer active in brain tissue, and the protective A allele creates a binding site for the transcription factor FOXO3⁶⁶ transcription factor FOXO3, while the risk G allele disrupts this binding. The traditional assumption was that this variant simply modulates alpha-synuclein levels, since it's near the SNCA gene. However, breakthrough CRISPR studies have revealed a more nuanced picture⁷⁷ breakthrough CRISPR studies have revealed a more nuanced picture: the protective A allele promotes normal neuronal differentiation and actually increases SNCA expression, while the risk G allele impairs neuronal development and reduces SNCA expression. This is counterintuitive — you'd expect higher alpha-synuclein to be worse for Parkinson's risk.

The resolution to this paradox likely lies in timing and context. The risk G allele appears to compromise dopaminergic neuron development during embryonic neurodevelopment⁸⁸ embryonic neurodevelopment
The effects manifest during fetal brain development, creating a diminished dopaminergic neuron population, leaving fewer neurons to spare when age-related degeneration begins decades later. Meanwhile, in adults who already have PD, having the GG genotype (which reduces alpha-synuclein expression in the cerebellum) may slow the accumulation of toxic protein aggregates, explaining the slower motor progression observed in clinical studies⁹⁹ slower motor progression observed in clinical studies.

The Evidence

A large case-control study in 2,205 Han Chinese participants¹⁰¹⁰ A large case-control study in 2,205 Han Chinese participants
Cheng et al. SNCA rs356182 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. Journal of the Neurological Sciences, 2016 found that the G allele was significantly overrepresented in PD patients (OR=1.470, p=2.3×10⁻⁸), with the GG genotype showing the strongest association (OR=1.620). This replicated findings from Caucasian populations, establishing rs356182 as a cross-ethnic risk factor.

A multi-site study of 810 Parkinson's patients¹¹¹¹ A multi-site study of 810 Parkinson's patients
Cooper et al. Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017 demonstrated that the GG genotype correlates with more tremor-predominant motor symptoms and predicts a 1-point per year slower UPDRS-III motor score progression. The variant was also associated with decreased SNCA expression in cerebellar tissue (p=0.005), suggesting region-specific effects on gene regulation.

The most mechanistically revealing study¹²¹² The most mechanistically revealing study
Prahl et al. The Parkinson's disease variant rs356182 regulates neuronal differentiation independently from alpha-synuclein. Human Molecular Genetics, 2023 used CRISPR to create precise hemizygous deletions at rs356182 in dopaminergic neuron cell models. Transcriptional profiling revealed that hundreds of genes involved in neurogenesis and axonogenesis were differentially expressed based on the allele present, with only minimal overlap with genes affected by SNCA knockout. This suggests rs356182 confers PD risk largely through mechanisms independent of alpha-synuclein levels.

A comprehensive meta-analysis¹³¹³ A comprehensive meta-analysis
Pihlstrøm et al. A comprehensive analysis of SNCA-related genetic risk in sporadic Parkinson disease. Annals of Neurology, 2018 identified rs356182 as one of at least three independent association signals at the SNCA locus, demonstrating that multiple genetic mechanisms at this locus contribute to PD risk in a non-redundant fashion.

Practical Implications

While there's no gene therapy or drug that specifically targets rs356182, the mechanisms it influences — neuronal health, oxidative stress, mitochondrial function, and dopamine system integrity — are all modifiable through lifestyle interventions. The evidence is strongest for aerobic exercise and antioxidant support.

Regular aerobic exercise demonstrates neuroprotective effects in Parkinson's models¹⁴¹⁴ Regular aerobic exercise demonstrates neuroprotective effects in Parkinson's models, improving mitochondrial function, reducing oxidative protein damage, and boosting neurotrophic factors like BDNF and GDNF in the substantia nigra. Exercise activates the Nrf2-ARE antioxidant response pathway, upregulates endogenous antioxidant enzymes, and may help preserve the dopaminergic neuron population that could be developmentally compromised by the G allele.

Dietary antioxidants — particularly beta-carotene and vitamin E¹⁵¹⁵ beta-carotene and vitamin E — have shown inverse associations with PD risk in prospective cohort studies. While these studies weren't stratified by rs356182 genotype, the biological rationale is sound: alpha-synuclein pathology generates oxidative stress, and individuals with variants affecting SNCA-related pathways may benefit more from antioxidant support.

For those with existing Parkinson's disease, knowing your rs356182 genotype may offer prognostic information. The GG genotype appears to predict a slower, more tremor-dominant course, which generally has a better prognosis and responds well to dopaminergic medications. However, this is population-level data — individual disease trajectories vary enormously based on other genetic factors, environmental exposures, and treatment responses.

Interactions

rs356182 is one of multiple independent SNCA risk variants. Other key variants include rs356219 (located in the promoter region) and rs356165, though these show minimal linkage disequilibrium with rs356182¹⁶¹⁶ these show minimal linkage disequilibrium with rs356182, meaning they segregate independently and can combine to increase risk additively. Individuals carrying risk alleles at multiple SNCA positions show incrementally higher PD susceptibility.

Beyond SNCA, gene-gene interactions have been documented between rs356219 (a related SNCA variant) and variants in LRRK2 and GAK genes¹⁷¹⁷ gene-gene interactions have been documented between rs356219 (a related SNCA variant) and variants in LRRK2 and GAK genes, suggesting that SNCA-pathway risk is modified by other Parkinson's genes. While specific studies haven't examined rs356182 in combination with LRRK2 or GBA variants, the biological pathways overlap — LRRK2 affects alpha-synuclein neurotoxicity and GBA mutations compromise lysosomal degradation of alpha-synuclein. Individuals with multiple risk variants across these pathways likely face compounded neurodegeneration risk, though the precise combined effects remain under investigation. Similarly, in carriers of LRRK2 mutations, the SNCA rs356219 variant modifies age of onset by approximately 4 years¹⁸¹⁸ in carriers of LRRK2 mutations, the SNCA rs356219 variant modifies age of onset by approximately 4 years, suggesting that SNCA variants interact with other PD genetic risk factors to influence disease timing and phenotype.

SLC19A1, known as the reduced folate carrier (RFC1), is the principal gateway through which folate vitamins and antifolate drugs enter cells. Every cell in your body depends on RFC1 to import the folate it needs for DNA synthesis and methylation. The same transporter is exploited by two major drug classes — antifolate chemotherapies (pemetrexed, methotrexate) and antifolate antibiotics — to enter their target cells. A variant in the second intron of SLC19A1, rs3788189, has emerged in pharmacogenomics studies as a modifier of how well these drugs work and whether side effects are likely.

The Mechanism

rs3788189 sits in intron 2 of SLC19A1 at chromosome position 21:45,516,669 (GRCh38). The gene lies on the minus strand, so the plus-strand T/G polymorphism corresponds to C/A on the coding transcript. This variant has also been annotated in the literature as IVS2(4935) G>A (intron 2, 4,935 bases into the intron). As an intronic variant, rs3788189 does not directly change the amino acid sequence of the RFC1 protein, but intronic variants can alter pre-mRNA splicing¹¹ pre-mRNA splicing
Intronic sequences contain branch points, polypyrimidine tracts, and splice enhancer/silencer sequences that regulate how exons are joined, create cryptic splice sites, affect mRNA stability, or alter transcriptional regulation through intronic enhancer elements. The exact molecular mechanism by which rs3788189 influences RFC1 expression or function has not been characterized, but the pharmacogenomics signal is consistent with functional consequences in folate and antifolate transport.

Note that rs3788189 is distinct from the well-characterized G80A coding variant (rs1051266, p.His27Arg), which is already in the GeneOps database. These are independent variants in the same gene with different functional implications.

The Evidence

The clearest pharmacogenomics signal comes from two small but consistent studies in patients receiving pemetrexed²² pemetrexed
Pemetrexed (Alimta) is an antifolate used for non-small-cell lung cancer and mesothelioma; it enters cells via RFC1 to inhibit folate-dependent enzymes, a modern antifolate chemotherapy that uses RFC1 for cellular uptake.

In a phase II perioperative study of 38 NSCLC patients receiving cisplatin plus pemetrexed, the TT genotype at rs3788189 was associated with improved disease-free survival³³ TT genotype at rs3788189 was associated with improved disease-free survival
Dy et al. J Thorac Oncol 2014 (p=0.0821), suggesting patients with two copies of the reference T allele derived greater benefit from pemetrexed-based chemotherapy.

In a larger pharmacogenomic study of 136 lung cancer and mesothelioma patients receiving pemetrexed/platinum⁴⁴ 136 lung cancer and mesothelioma patients receiving pemetrexed/platinum
Corrigan et al. Pharmacogenomics J 2014, rs3788189 was among three SLC19A1 polymorphisms independently associated with overall survival, supporting the hypothesis that this intronic variant influences RFC1-mediated pemetrexed transport.

A meta-analysis of 16 publications covering 1,510 patients on pemetrexed or gemcitabine identified SLC19A1 IVS2(4935) G>A — corresponding to rs3788189 — as a predictor of grade 3+ leukopenia in American patients⁵⁵ SLC19A1 IVS2(4935) G>A — corresponding to rs3788189 — as a predictor of grade 3+ leukopenia in American patients
Zaïr & Singer, Pharmacogenomics 2016. This hematological toxicity signal suggests that the G allele may be associated with impaired RFC1-mediated pemetrexed transport efficiency or altered folate competition during treatment, leading to differential drug exposure in bone marrow progenitor cells.

The evidence base is limited — most studies are small, the mechanism is not characterized at the molecular level, and no clinical guidelines (CPIC, DPWG) currently exist for this variant. The evidence level is therefore rated emerging.

Practical Actions

For people with GG or GT genotypes who are candidates for pemetrexed or methotrexate treatment, sharing this pharmacogenomic result with their oncologist or rheumatologist provides potentially useful context — particularly given the leukopenia signal in the meta-analysis. Pemetrexed requires standard folic acid and vitamin B12 supplementation before each cycle regardless of genotype (per prescribing protocol), but this variant may influence monitoring intensity.

From a nutritional standpoint, since RFC1 is also the main folate transporter, this variant may modestly affect baseline folate transport efficiency. The G allele may be associated with slightly altered intracellular folate availability, though this has not been studied in nutritional contexts independent of antifolate chemotherapy.

Interactions

The most clinically significant interaction is with the coding variant rs1051266 (G80A, p.His27Arg) in the same gene. rs1051266 reduces RFC1 transport function through a structural change in transmembrane domain 1; rs3788189 may additively affect transport through an independent regulatory mechanism. Carriers of risk alleles at both sites within SLC19A1 may have more pronounced impairment.

The folate pathway interaction extends to MTHFR (rs1801133 C677T, rs1801131 A1298C): if MTHFR activity is reduced AND RFC1 transport is impaired, intracellular methylfolate may be doubly compromised, amplifying the importance of methylfolate supplementation over synthetic folic acid.

Pain and the medications used to treat it are profoundly personal. The same opioid dose that barely touches one person's pain may overwhelm another's reward circuits. Part of that individual variation is genetic — and some of it traces back to the chromatin architecture of pain-relevant genes themselves. rs3791033 is an intronic variant¹¹ intronic variant
A change within a non-coding region of a gene, located within intron 8 of KDM4A at position c.1163+387 on chromosome 1 in KDM4A, a histone demethylase that regulates which genes are switched on or off in the brain's pain and reward systems. The C allele was identified as one of only two genome-wide significant variants for problematic opioid prescription use in one of the largest studies ever conducted on opioid genetics.

The Mechanism

KDM4A (lysine demethylase 4A²² lysine demethylase 4A
Also known as JMJD2A or JHDM3A; the gene encodes a JmjC-domain Jumonji family demethylase, OMIM 609764) removes trimethyl marks from histone H3 at lysines 9 and 36 (H3K9me3 and H3K36me3). These marks are repressive — regions of chromatin bearing them are condensed and transcriptionally silent. By erasing these marks, KDM4A opens chromatin at specific gene promoters and allows transcription to proceed. At pain-relevant loci and in dopaminergic reward circuits — where H3K9 methylation status tightly controls gene expression — variation in KDM4A activity can shift the transcriptional landscape of pain processing and opioid reward.

rs3791033 lies in an intron, so it does not alter the KDM4A protein sequence. Its effect is likely regulatory: altering splicing efficiency, intron retention kinetics, or binding of regulatory RNA-binding proteins, any of which could modulate KDM4A expression levels in relevant tissues. The mechanism by which this specific intronic change influences opioid use behavior remains under investigation.

The Evidence

Sanchez-Roige et al. (2021)³³ Sanchez-Roige et al. (2021)
PMID 34728798, Molecular Psychiatry, N=132,113 European-ancestry 23andMe participants, ~21% cases conducted a GWAS of "problematic opioid prescription use" — defined as using prescribed opioids not as prescribed — as a proxy phenotype for opioid use disorder risk. Among 132,113 participants, only two loci reached genome-wide significance (p ≤ 5×10⁻⁸): rs3791033 near KDM4A and rs640561 near LRRIQ3. The genetic correlation between this phenotype and clinically diagnosed opioid use disorder was rg = 0.64–0.80, validating the proxy approach. Additional genetic correlations were found with alcohol dependence (rg = 0.74), chronic pain, depression, and insomnia — consistent with the known comorbidity structure of opioid misuse.

The study did not report specific odds ratios or beta coefficients for the lead variants in the abstract, which is a limitation. The finding represents discovery-level evidence: genome-wide significant in a large, well-powered study, but requiring replication in independent clinical cohorts with direct OUD diagnosis and functional follow-up.

Contextualizing the biology, Holen et al. (2023)⁴⁴ Holen et al. (2023)
PMID 37252880, Addiction Biology, ~15,756 OUD cases and ~600,000 psychiatric controls identified 14 novel OUD loci using a cross-disorder conditional FDR approach, including DRD2, FURIN, and MHC region — establishing shared genetic architecture between OUD and major psychiatric disorders. KDM4A's epigenetic regulatory role connects this variant to the broader landscape of transcriptional dysregulation in addiction neuroscience.

Practical Actions

The C allele of rs3791033 signals higher individual susceptibility to problematic opioid use — using opioids in ways that deviate from prescribed instructions, which is an early behavioral marker for developing opioid use disorder. This does not mean opioid medications should never be used; rather, it suggests heightened vigilance when opioids are prescribed for pain management.

CC homozygotes carry two copies of the risk allele and face the greatest concern. Discussing genetic risk explicitly with treating physicians allows for proactive steps: careful dosing titration, shorter prescription durations, preference for non-opioid first-line analgesics where clinically appropriate, and early monitoring for signs of dose escalation or dependence. CT heterozygotes carry an intermediate signal worth noting, particularly for anticipated longer-term opioid exposure (post-surgical recovery, chronic pain management).

Non-opioid pharmacological alternatives include NSAIDs, COX-2 inhibitors, anticonvulsants (gabapentin, pregabalin), SNRIs (duloxetine for neuropathic pain), tricyclic antidepressants for neuropathic and central sensitization pain, and topical agents (lidocaine patches, capsaicin). Interventional options — nerve blocks, spinal cord stimulation — are worth earlier consideration in surgical and chronic pain contexts for individuals with elevated genetic opioid risk.

Interactions

rs3791033 has been studied as an independent locus. The GWAS that identified it found a second significant hit at rs640561 near LRRIQ3, though these are on different chromosomes and are not in linkage disequilibrium. The broader opioid use disorder genetic landscape overlaps with OPRM1 rs1799971 (the A118G variant, the best-studied opioid receptor variant, which alters mu-opioid receptor binding affinity) — though rs3791033 and OPRM1 act through distinct mechanisms (epigenetic regulation vs. receptor function) and both may contribute independently to overall opioid response phenotype.